ABSTRACT
INTRODUCTION
MiRNAs are evolutionary conserved small non coding RNAs that are known to posttranscriptionally inhibit protein coding genes, by affecting their translation and/or mRNA stability (1) . They are derived from longer precursor molecules, are incorporated to the RNA-induced silencing complex (RISC) and interact with complementary regions mainly within the 3' Untranslated Region (3'UTR) of their target mRNAs (2) . Evidence from the early days of miRNA research, and up to the present day, has suggested that the expression of some miRNAs is highly regulated in a temporal-and region-specific manner and that they participate in divergent biological processes (3).
In the vertebrate nervous system, miRNAs have been shown to play an important role during development (4) and in regulation of synaptic plasticity (5) . A subset of miRNAs are abundantly expressed in the human brain (6, 7) and have been implicated in numerous brain diseases (8) (9) (10) (11) (12) (13) . However, very little is known about their expression and function in the human prefrontal cortex (PFC), a brain area responsible for high order cognitive functions, which displays delayed maturation and is disrupted in patients with psychiatric disease (14, 15) .
Brain Derived Neurotrophic Factor (BDNF) plays a prominent role during cortical development and maturation (16) , and alterations in BDNF expression have been reported in a plethora of neuropsychiatric diseases (17) . Interestingly, pyramidal neurons -the primary source of BDNF in cerebral cortex -express high levels of DICER, an RNAse III endoribonuclease and key molecule for miRNA biogenesis, as well as components of RISC, such as eIF2c (18) . Furthermore, the 3' UTR of human BDNF is predicted according to computational analysis to include numerous miRNA target sites that show a high degree of conservation between different mammalian species (19) . These findings, taken together, point to a potential role for miRNAs in the control of cortical BDNF expression. However, to date, this hypothesis has not yet been tested.
Here, we present evidence that multiple miRNAs, including a subset of the miR-30 family, are involved in fine-tuning of BDNF expression specifically during late maturation and aging of human prefrontal cortex. Our findings suggest that BDNF expression in human cerebral cortex is regulated by a complex system of small RNAs, which in turn display lamina specific enrichment and are differentially regulated during development. These findings provide the first evidence for the miRNA pathway acting as a key regulator of BDNF expression during maturation and aging of human prefrontal cortex.
RESULTS

In silico analysis of putative miRNA target sites within BDNF 3'UTR
Potential miRNA target sites within the 3Kb of BDNF 3' UTR were identified by combining three in silico tools: TargetScan 3.1 (19) , Pictar (20, 21) and RNAhybrid (22) . Altogether, 17 distinct target sites -all of which appear to be highly conserved in various mammalian species (human, chimp, dog, mouse, rat) -were found, which potentially could interact with 26 different miRNAs ( Fig. 1 and Supplemental table 3).
Next, we used an array-based approach to measure the expression of these 26 candidate miRNAs and identified 10 miRNA species that were present at moderate or high levels in the adult human parietal cortex; for the remaining miRNAs, levels were very low or indistinguishable from background (Supplemental Figure 1A) . We then compared our array results with published microarray data on adult human prefrontal cortex (11) . Remarkably, all but one (miR-495) showed a similar order of expression in prefrontal and parietal cortex (Supplemental Figure 1B) .
Notably, the target site(s) for each of the 10 expressed miRNAs -which segregate into five different miRNA families (miR-103/107, miR-191, miR-16/195, miR-30a-5p/b/c/d, miR-495) -were in close vicinity to the two proximal (out of four total) BDNF 3'UTR polyadenylation sites (Fig. 1) ; in adult cerebral cortex, the bulk of BDNF transcript extends beyond these two proximal polyA sites (25, 26) . This would suggest that a large fraction of BDNF transcript could be targeted by the miRNAs listed above.
Laminar and cellular specificity of miRNAs expressed in PFC
We wanted to examine the laminar and cellular expression pattern of the predicted miRNAs in adult human PFC; BDNF transcript is found in putative pyramidal neurons positioned within layers II-VI (27, 28) . Cellular labeling was weak or not discernible from background in sections processed by LNA-ISH for miR-1 and miR-10a ( Fig. 2A,H and Supplemental Fig. 2 ), two miRNAs expressed at very low or non-detectable levels respectively according to our microarray data (Supplemental Fig. 1A ). In contrast, miR-128a, a reportedly pan-neuronal miRNA marker (29) , also detected at high levels in our microarray analysis (data not shown) , was robustly expressed throughout the full thickness of PFC ( Fig. 2A) . Therefore, we conclude that LNA-ISH is applicable to human postmortem brain tissue, which is in accordance to previous reports (30) . Next, we studied prefrontal expression patterns of the 10 predicted miRNAs with 8 probes (due to one-base-differences, a single probe was applied for miR-103/107 and for miR-30a/d; see also Supplemental Table 2 ). Each of the 8 probes revealed a distinct laminar expression ( Fig. 2A,H and Supplemental Figure 2 ). For example, miR-30a showed robust labeling in the upper cortical layers, including a subset of large, putative pyramidal neurons primarily residing in layer III ( Fig. 2A,B) . In contrast, labeling in PFC layers V and VI was very weak or non-detectable ( Fig. 2A,E) . To further confirm these lamina-specific differences, we assayed miR-30a levels by qRT-PCR separately for the upper (including layers II and III) and lower (mainly V and VI) layers of the cortex. Indeed, levels of miR-30a were approximately 2.5 fold higher in the upper as compared to the deeper layers (Fig. 2J) . In contrast, neither BDNF mRNA ( Fig. 2J ) nor protein levels (data not shown) showed significant differences between the upper and lower layers; the latter finding may not be too surprising, however, given that BDNF protein produced in pyramidal neuron somata could potentially be distributed via their processes to other cortical layers and neuronal populations further removed from the site of synthesis (33) .
In addition, expression in pyramidal neurons was further confirmed in sections processed by LNA-ISH followed by immunolabeling for a neurofilament epitope selectively expressed by a subset of pyramidal neurons (31) (Fig. 2I) and by RT-PCR from laser-capture dissected pyramidal neurons (Supplemental Fig. 2) . Expression of miR-495 was highly restricted and limited to a subpopulation of cells positioned in and around layer II ( Fig. 2H and Supplemental Fig. 2 ). Cellular labeling for miR-16 in tissue sections was weak and mostly confined to deeper portions of cortical gray matter (Supplemental Fig. 2 ). It is possible that the high levels of miR-16 in mature erythrocytes (32) could have contributed to the comparatively high but variable levels of expression in whole tissue homogenates assayed by array (Supplemental Figure   1 ).
Among all miRNAs tested, only miR-103/107 was enriched in upper cortical layers and was also expressed in white matter. This particular finding is in good agreement with a recent report showing the same laminar enrichment in superior and middle temporal gyrus (13) . Intriguingly, however, none of the miRNAs included in our study showed discernable layer specificity in mouse cerebral cortex (Supplemental Fig.2 and data not shown), suggesting that miRNA expression in cerebral cortex shows important differences between human and rodent. In conclusion, miR-30a and other members of the miR-30 family, and several additional miRNAs predicted to interact with the 3'UTR of BDNF are abundantly expressed in adult human PFC, with distinct laminar specificity.
Validation of human BDNF 3'UTR miRNA target sites
To determine whether the candidate miRNAs described above target the 3'UTR of human BDNF mRNA, we constructed a luciferase reporter plasmid with a 551 bp fragment of human BDNF 3'UTR containing all the highly predicted miRNA target sites fused to the 3' of the luciferase gene (Fig. 3A) . We utilized CMV driven vectors that encode for each of the following miRNA precursors -miR-30a, miR-30b, miR-30c, miR-107, miR-191 and miR-195 (Supplemental Fig. 3 ). Since the endogenous levels of these miRNAs varied, transfection of these plasmids in HEK293 cells resulted in various degrees of overexpression of the mature miRNAs (Fig. 3D) . It should be noted that, in these assays, miR-16 and miR-495 were not included because of uncertain (miR-16), or highly restricted (miR-495) expression in the cortex. Furthermore, because of high sequence similarity (one single nucleotide difference), miR-30d and miR-103 are predicted to have very similar effects on BDNF 3'UTR with miR-30a and miR-107 respectively; hence these miRNAs were not tested separately.
Due to the fact that miR-30a was enriched in layer III pyramidal neurons ( Fig.   2 ), which are a critical component of prefrontal cortical neuronal networks (33) , and one of the major sites of BDNF synthesis (27) , we anticipated that this miRNA might be particularly important for the posttranscriptional inhibition of BDNF. Additionally, in silico analysis of the interaction between miR-30 miRNAs and BDNF 3'UTR indicated a more favorable thermodynamic interaction of miR-30a compared to miR-30b and miR-30c, resulting from a higher 3' end complementarity of miR-30a with the 3'UTR (Supplemental Fig. 3 ). Indeed, results from the luciferase assay showed that overexpression of miR-30a, but not miR-30b and miR-30c, lead to a significant decrease in activity of the reporter (Fig. 3B) . Among the remaining miRNAs tested, only miR-195 induced a significant reduction in luciferase activity (Fig. 3B) .
Importantly, no changes in reporter activity were observed after transfection of a miR30a-based non silencing control ("NSC30", Fig. 3B ), in which the seed sequence (nt 2-7, see Fig. 4D for details) was mutated in order to disrupt complementarity with BDNF 3'UTR target sites. Furthermore, the NSC30 mature sequence was not predicted to target the 551bp of BDNF 3'UTR, according to RNA hybrid software (data not shown).
Notably, processing of the miR-30a precursor can lead to two microRNAs, miR-30a-5p and miR-30a-3p (34, 35) . Interestingly, both our microarray (Supplemental Fig. 1A) and in situ hybridization experiments ( Fig. 2A and data not shown) indicate that expression of miR-30a-5p is much higher than miR-30a-3p in the human cerebral cortex. Therefore, we modified the miR-30a precursor sequence by replacing one or two Watson-Crick base pairings with G-U wobbles at the 5' end and vice versa for the 3'end (marked by arrows in Fig. 3C ). The rationale was to destabilize the 5' relative to the 3' end of the precursor, which is expected to shift relative levels of mature miRNA towards the 5' product (36) . Indeed, transfection with this modified miR-30a precursor (m30a-5p, see Fig. 3B -D) resulted in a 3-fold increase in levels of mature miR-30a-5p, as compared to transfection with the wildtype form of the precursor (Fig. 3D ). There was a ~36% reduction in reporter activity in cells transfected with m30a-5p, compared to ~24% in cells transfected with wildtype miR-30a precursor (Fig. 3B) . Finally, it is worth mentioning that there are two potential miR-30 interaction sites within the BDNF 3'UTR, although the second site (Fig. 1, 3A ) is likely to be less functional due to the presence of a G-U wobble in the seed sequence (first site, bp 397-402; second site, bp 680-685 of BDNF 3'UTR, see Supplemental decrease in reporter activity in cells transfected with miR-30a precursor relative to a scrambled precursor control (N = 3 independent experiments, data not shown).
Furthermore, we co-transfected both miR-30a and miR-195, which independently reduced luciferase activity, with half the amount needed to exert the observed significant inhibitory effect (375ng of each per well), a concentration that for miR-30a was unable to induce significant repression (data not shown). The combination of these two miRNAs even in such lower concentrations resulted in a significant (~31%) reduction in luciferase activity (Fig. 3B ). This level of inhibition was not, however, significantly higher than the independent inhibitory effects of miR-30a (~24%) and miR-195 (~28%), so that the possibility of a synergistic effect remains to be clarified. These results indicate that a subset of miRNAs expressed in PFC, including miR-30a, can exert an inhibitory interaction with BDNF 3'UTR sequences.
MiR-30a negatively regulates BDNF protein in neurons.
The validation of miR-30a:BDNF 3' UTR interaction with luciferase reporter assays in two different cell lines, and its higher relative expression in neurons that are able to synthesize BDNF compared to some of the other candidate microRNAs, including miR-195, suggest that miR-30a is more likely to be a potential regulator of neuronal BDNF expression. To pursue this further, we used a lentivirus-based system to overexpress miR-30a precursor in cultured neurons (derived from E14.5 rat forebrain progenitor cells, see Methods) ( Fig. 4A ) and then assayed BDNF protein by ELISA. A lentivirus expressing miR-30a-based non-silencing control ("NSC30", Fig. 4D ) was also included in these experiments. Transduction efficiencies were verified with GFP expression and included a majority of cells (on average, 60%) (Fig. 4A ). Cultures transduced with miR-30a showed a 2-4 fold increase in mature miR-30a levels, as measured by qRT-PCR (Supplemental Fig. 4 ). There was a significant, approximately 30% decrease in BDNF protein levels in neuronal cultures overexpressing miR-30a (Fig. 4B) . In contrast, the non-silencing control -which was identical to miR-30a except for 3 mutations in the seed sequence (Fig. 4C,D) -did not alter neuronal BDNF levels. Notably, miRNAs exhibiting partial complementarity to their mRNA target (such as miR-30a:BDNF 3'UTR, Fig. 4C ), predominantly block translation, but additional mechanisms involving mRNA decay have also been reported (1) . Therefore, we assayed BDNF mRNA in our cultures, and no changes were observed (Supplemental Fig. 4 ). We conclude that miR-30a exerts an inhibitory effect on BDNF translation in neurons.
Expression of selected miRNAs in PFC shows inverse correlation with BDNF protein during late adolescence and adulthood.
Our experiments ex vivo described above strongly suggest that miR-30a-5p regulates BDNF protein levels, via interaction with a conserved sequence located in the proximal portion of BDNF 3'UTR. Based on this observation, it could be possible that there is an inverse relationship between BDNF and miR-30a levels in (human) PFC tissue. Furthermore, it has been shown that when multiple miRNAs target a specific transcript, synergistic effects could lead to more robust target regulation as compared to each miRNA separately (38) . Given this potential cooperativity in miRNA targeting and the limitations of our luciferase assay to address this issue, we wanted to investigate if their combined effects on BDNF levels during various stages of PFC development could be physiologically relevant.
Towards this end, we first used qRT-PCR to assay expression levels of the following miRNAs using seven sets of primers (with confirmed sequence specificity, 5 ). Given these highly dynamic differences in miRNA levels during the course of PFC development, and especially in the mature PFC, we asked whether these changes relate to BDNF protein content.
To address this question, we measured BDNF protein by ELISA in the same postmortem specimens. Our data showed that both BDNF protein and mRNA are upregulated during the early stages of postnatal PFC development, yet appear to be discordant during late adolescence and adulthood (Fig. 5A,C,D) . In addition, there was, as expected, a positive correlation between BDNF mRNA and protein, in the entire developmental cohort (r=+0.379, p=0.025) and, independently, in samples less than 15 years of age (r=+0.525, 0.021). However, there was no significant correlation in samples more than 15 years of age (data not shown).
Strikingly, in mature (15-84 years old) PFC a highly robust, inverse correlation between the expression of the 7 miRNAs as a group and BDNF protein levels (Fig.   6A ,B) was observed. Furthermore, there was an inverse correlation between PFC BDNF levels for the same age group (15-84 years old), and for three miRNAs independently (miR-30a, miR-30d and miR-191) (Fig. 6C ). These statistical associations were highly specific, because the (neuronal enriched) miR-128a -which is not predicted to target BDNF -had no correlation to BDNF protein levels in any age group (Fig. 6C and data not shown) . In addition, no correlation was detected between BDNF mRNA and miRNA expression levels (data not shown). Taken together, these findings suggest that the orchestrated developmental expression of a group of miRNAs including miR-30a might exert an inhibitory effect on BDNF translation especially in the mature PFC.
Transcriptional mechanisms regulating BDNF expression in immature PFC
In contrast to the significant findings in adults, there were no significant correlations between BDNF protein and the 7 miRNAs as a group, or individually, in subjects less than 15 years old ( Fig. 6D and data not shown) . However, we noticed that levels of BDNF mRNA were increased up to 3-fold after birth, consistent with an earlier report (28) , but did not change significantly thereafter (Fig. 5D ). These findings raise the possibility that BDNF levels at these earlier stages of PFC development are less dependent on miRNA-mediated post-transcriptional regulation and instead are regulated on the level of gene expression.
In order to address this issue, we measured levels of H3-trimethyl-lysine 4 -an open chromatin mark related to transcriptional activity (39) that can be measured in postmortem brain (40) -at defined BDNF promoter sequences in PFC of fetal, child and adult samples. We assessed BDNF gene promoters I and IV (P1 and P4, Fig.   7A ), as these are known to be epigenetically regulated in rodent cerebral cortex (41) (42) (43) (44) . As a control we also checked for changes of the same chromatin marker within the newly recognized promoter IX (P9, Fig. 7A ), which reportedly shows only very low levels of activity in brain (45) . Indeed our results showed a significant increase in histone methylation at BDNF P1 occuring after birth (Fig. 7B) , and at BDNF P4 after childhood (Fig. 7C) . In contrast, histone methylation at BDNF P9 were very low and indistinguishable from background in all samples (data not shown). These results suggest that while miRNAs exert a robust effect on BDNF levels in mature and aging PFC, chromatin remodeling and transcriptional mechanisms might play a more prominent role at the earlier developmental stages.
DISCUSSION
Using multiple approaches, including microarray, LNA-ISH and qRT-PCR we identified a group of miRNAs that were abundantly expressed in different layers of human PFC and predicted to target a specific region within human BDNF 3'UTR. Notably, albeit the sequence of these miRNAs is completely preserved in multiple mammalian species, there was lamina-specific expression in human but not in mouse neocortex. A subset of these miRNAs (miR-30a,b,c,d, miR-103/107, miR-191, miR-195) showed an inverse correlation with BDNF protein levels in the adult, but not in the immature human PFC. Among these miRNAs, miR-30a exerted a significant inhibitory interaction with BDNF 3'UTR in functional assays and decreased BDNF protein levels in neuronal culture.
The significant inverse correlation between the group of the selected miRNAs and BDNF protein levels from late adolescence to old age suggests that these miRNAs could participate in post-transcriptional fine-tuning of BDNF expression in adult PFC, including the periods of late maturation and aging. Interestingly, BDNF mRNA levels in human PFC have been shown to increase from infancy to young adult age but subsequently are maintained at roughly the same levels during adulthood and old age (28) . In contrast, BDNF protein levels are reportedly reduced during the aging of human PFC (46) . Therefore, our studies could potentially explain these discrepancies in age-dependent changes of BDNF mRNA and protein, by showing that BDNF protein levels in mature and aging PFC could be driven in part by the post-transcriptional regulation mediated by BDNF-related miRNAs ( Fig. 5 and Supplemental Fig. 5 ).
In contrast, the absence of significant correlations between BDNF protein and the selected miRNAs in the younger PFC samples could be partly attributed to a more prominent transcriptional control of the BDNF gene in the immature PFC (defined here as the fetal and 0 -15 years old samples). This hypothesis is further supported by dynamic increases in open chromatin-associated histone methylation at a subset of BDNF gene promoters during postnatal PFC development (Fig. 7) . It has to be noted, though, that due to technical limitations we did not explore the expression levels of all BDNF alternative mRNA transcripts and the chromatin status of all BDNF gene promoters. In addition to the two layers of regulation outlined in the present studymicroRNAs-mediated inhibition and chromatin remodeling -additional mechanisms that could affect expression and function of BDNF regulation may involve antisense non-coding transcripts originating from the BDNF locus (45) .
The presence of miR-30a in large layer III pyramidal neurons of human PFC, as observed in the present study by qRT-PCR, LNA-ISH and laser capture ( Fig. 2 and Supplemental Fig. 2) , is of particular interest given the fact that this neuronal population displays alterations in dendritic spine density (47) and soma size (48) in schizophrenia, a disease where deficits in BDNF levels have been reported in some postmortem cohorts (15, 26) . In this context it is intriguing that the developmental dynamics of miR-30a expression in human prefrontal cortex include a pronounced decline in miR-30a levels during the late phase of PFC maturation (ages 15-41 years old), which coincides with the age of onset of the clinical symptomatology of psychiatric disease (33) .
According to our present study, at least 7 different microRNAs could contribute to the regulation of BDNF expression in human PFC (miR-30a-5p, miR-30b,c,d, miR-103/107, miR-191, miR-195). Interestingly, miR-107 was very recently shown to be significantly downregulated in Alzheimer's disease (13) . Furthermore, in a previous study, miR-30b and miR-195 were shown to be reduced in schizophrenia PFC (11) . Of note, miR-30a-3p was shown, by qRT-PCR, to be increased in cases of the same study; this miRNA is derived from the same precursor as miR-30a-5p, although its interactions with BDNF remain unclear. The potential role of these miRNAs for BDNF regulation and signaling in diseased brain remains to be clarified.
It is noteworthy that the BDNF related miRNAs that were the focus of our study are also predicted to target numerous genes related to synaptogenesis, neuronal migration, neuronal growth and differentiation, according to multiple computational analysis tools (19) (20) (21) . In this context, the miR-30 family of microRNAs is predicted to target multiples genes (19, 49) According to the present study, there is laminar specificity for several miRNAs expressed in human PFC, including miR-30a, miR-103/107, miR-495 ( Fig. 2 and Supplemental Fig. 2) ; for miR-103/107, this was also observed in (human) temporal neocortex (13) . In striking contrast, the same miRNAs appeared to be either expressed evenly throughout layers II-VI of mouse neocortex (including frontal areas), or in the case of miR-495, below the detection limit (Supplemental Fig. 2 and data not shown). It is possible that these species-related differences in cortical miRNA patterns could result in a more sophisticated lamina-specific regulation of BDNF expression in the human cortex. 
MATERIALS AND METHODS
Postmortem studies
Postmortem samples from 37 subjects, obtained from the dorso-rostral pole of the frontal lobe (Brodmann's Area 10), were included in this study. All procedures were approved by the review boards of the participating institutions. All brains were fresh- Table 1 . For all experimental procedures, each assay included samples from all age groups. Each control brain was subjected to neuropathological examination to rule out neurodegenerative disease.
RNA isolation
Small RNAs (<200nts) were isolated by using the mirVANA PARIS kit (Ambion), according to the manufacturer's instructions and treated with DNase I for 30 minutes at 37°C. Then, samples were incubated at RT for 2 min in DNase I inactivating buffer (Ambion -RNAqueous kit), followed by centrifugation (13,000 x g) for 1.5 min and supernatant was stored at -80°C. The mirVANA PARIS kit was also used for the extraction of large (>200nt) RNA that was used for measurement of BDNF mRNA.
The mirVANA PARIS kit (Ambion) was used for total or small RNA isolation from rat neuronal cultures and the RNAqueous Micro kit (Ambion) was used for total RNA extraction in HEK-293 cells. All samples were treated with DNase I to avoid DNA contamination. For determination of RNA quality RNA integrity numbers (RIN) were calculated using the Agilent 2100 bioanalyzer and according to manufacturer's instructions.
RNA quantification
Amplicons were generated for 5S rRNA and the following miRNAs (see also Supplemental Table 2 rRNA with primers shown in Supplemental Table 2 .
MicroRNA microarray
MiRNA Table 2 ). The 20 ml of hybridization buffer was made of 50% deionized formamide / 2xSSC / 10% dextran sulfate / 500µg/ml sperm DNA / 0.25 mg/ml yeast t-RNA / 0.2 mg/ml BSA / 50 µg/ml heparin / 2.5 mM EDTA / 0.1% Tween-20 in 2. 
BDNF immunoassay
Protein was extracted with the mirVANA PARIS kit according to manufacturer's instructions and after centrifugation the supernatants were used for estimation of total protein with BCA micro-kit (Pierce). BDNF levels were essayed with Enzyme-Linked ImmunoSorbent Assay (ELISA) and with the use of BDNF ELISA kit (Chemicon) according to manufacturer's instructions.
Immunohistochemistry, tissue dissection and laser capture microdissection procedures:
Sections, 8-10 µm thick, were cut from frozen unfixed postmortem human tissue blocks (adult PFC -BA10) on a cryostat (Leica) on plain non-coated glass slides, stored at -80 o C, than before staining they were dried for 2 mins, fixed in 100% acetone for 2 min , air dried for 30sec, then washed in PBS and processed for 
Chromatin Immunoprecipitation in postmortem tissue
Chromatin Immunoprecipitation in postmortem tissue from human PFC of different age was done as described previously (40) by using 70-100mg of tissue and with the primers shown in Supplemental Table 2 .
Luciferase assays
Ambion's pMIR-REPORT luciferase reporter plasmid was engineered to include a 
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